About: tuberculosis
Tuberculosis patients in Ukraine at risk, some refugee groups to be tested
Russia’s invasion of Ukraine has put tuberculosis (TB) patients inside the country at high risk due to the lack of access to treatment, while countries receiving refugees have been advised to screen and test certain groups.
Better tools are need to end tuberculosis and anti-microbial resistance
We need better tools to end TB and AMR, and the EU can and must lead these efforts, writes Nicolae Ștefănuță.
COVID-19 and Ukraine war reversed gains in fighting tuberculosis
The global number of tuberculosis (TB) deaths increased last year for the first time in over a decade due to disruptions in vaccination and diagnosis created by the COVID-19 pandemic.
Bulgaria pins hopes on BCG vaccine against coronavirus
In the worldwide battle against COVID-19, scientists are investigating whether a century-old tuberculosis vaccine might offer some additional protection against the novel coronavirus.
Empowering patients for a better health
Concepts like the multisectoral approach and people-centred health services are turning the healthcare sector upside down, putting people back at the core and breaking silos for implementing cross-sectoral policies.
People-centred healthcare arrives at the European Parliament
A different approach to healthcare looping around health needs and expectations of people rather than diseases was touched in an event at the European Parliament, where participants and speakers called for more patient empowerment in the EU health agenda.
Global health research – a chance for Moedas to shape his legacy
Lawmakers must take the chance to strengthen the EU's investment in treatments for poverty related diseases and make the EU a hub for research excellence, writes José Inácio Faria MEP.
Horizon Europe – A global health prescription for the EU
EU research and innovation ministers need to increase funding for Horizon Europe and show they are serious about combating poverty-related diseases, says Cécile Vernant.
Health and vaccine research set to lose out from new EU research budget
The European Commission may be planning to hike spending for its flagship research programme, but health and scientific research, particularly into new vaccines, was not one of the winners from the proposal announced on Thursday (7 June).
EU leaders – Making Europe the world leader on global health must be your legacy
The next EU budget must establish the bloc as the world leader in financing the health research that will end poverty-related diseases, writes Cecile Vernant.
EU overtakes UK on medical research for developing world
Bill Gates, the US businessman turned philanthropist, is in Brussels on Thursday (16 February) to unveil a new report into medical research and development for the developing world that shows the EU has overtaken the UK in terms of funding.
SDG progress hampered by insufficient mortality data
Life expectancy is at its highest in Europe and the average is globally rising at a significant rate except in Africa, according to new figures released by the World Health Organisation. But its work is being hurt by a lack of data to analyse. EURACTIV Germany reports.
Corruption continues to hinder Global Fund’s work
The Global Fund has financed anti-malaria programmes in 100 countries since its foundation in 2002. However, there are flaws in the system and the spectre of corruption is ever present. EURACTIV’s partner Der Tagesspiegel reports.
UNITAID: Health spending in developing countries brings a ‘five-fold return’
Access to new treatments for the big pandemics in Africa has improved, thanks to falling prices, and the ending of medical patents, Philippe Duneton told EURACTIV France.
Call for coordinated European response on tuberculosis
Every year on World Tuberculosis (TB) Day, the World remembers those who have died and the millions that suffer every year from of an infection that is both preventable and curable, write a group of health experts.
New TB drug for children finally developed
Tuberculosis was discovered late in the 19th century, with antibiotics introduced for its treatment halfway through the 20th. Now, treatment specifically for children is set to be rolled out. EURACTIV's partner El País - Planeta Futuro reports.
Health experts to take fight to TB
A new strategy to fight and eventually eradicate tuberculosis is expensive - but it may be the only way to tackle a disease that is becoming resistant to medication and killing the world's poorest. EURACTIV's partner El País - Planeta Futuro reports.
WHO: More work needed to eradicate tuberculosis
A new study by the WHO has shown that the number of tuberculosis cases per year has nearly halved, but that there is still a lot of work to be done. EURACTIV Germany reports.
Drug-resistant TB threatens to kill 75 million people by 2050
Over the next 35 years, multidrug-resistant tuberculosis will kill 75 million people and could cost the global economy a cumulative $16.7 trillion (€15.3 trillion) - the equivalent of the European Union's annual output, a UK parliamentary group said on today (24 March).
Political action is needed to stop Tuberculosis
Greater political commitment to fight tuberculosis is urgently needed, as Eastern Europe is struggling with some of the highest rates of drug-resistant tuberculosis (MDR-TB) worldwide, writes Evan Lee.
Report: Tuberculosis still raging in Eastern Europe
About a thousand people still contract tuberculosis daily in Europe and Central Asia, despite an overall decline of the disease, a report by the Europe Centre for Disease Prevention and Control (ECDC) revealed Tuesday (17 March).
As EU aid ends in Indonesia, communities take over
In 2019, the European Union will terminate a number of its health support programmes in middle-income countries, including in Indonesia. This will put a lot of pressure on the archipelago's healthcare system, which is heavily staffed by volunteers. EURACTIV reports from Jakarta.
Developing countries urged to produce TB vaccines locally
Even though one third of the global population have the microbes that cause tuberculosis (TB), pharmaceutical companies still have little incentive to produce the drugs that can combat the deadly but curable disease.